Abstract 5907
Background
The most recent consensus statement on the use of liquid biopsies (circulating tumor DNA – ctDNA testing) has been that it is not yet ready for prime time. However, in patients with metastatic colorectal cancer (mCRC), there is significantly more ‘shedding’ of DNA detectable in blood allowing this test to be of value. We aimed at reporting the concordance of liquid biopsies based on clonality and timing of testing in patients with mCRC.
Methods
A total of 92 mCRC patients were identified who had both a commercially available liquid and tissue next generation sequencing assay done from December 2016 to February 2019. Arbitrarily, mutations were classified as clonal or subclonal based on the 50% cutoff of the highest variant allele frequency (VAF) reported. Concordance rates, including clonal (BRAF-V600E/ RAS), subclonal and amplification concordance were calculated separately for patients for whom the liquid biopsy testing was done before initiation of treatment (n = 27) and after initiation of treatment (n = 65).
Results
Clonal concordance rates were 96.3% for patients when the liquid biopsy was done before initiation of treatment versus 64.6% for patients when the test was obtained after they were already on some systemic therapy (p value: 0.001). Similarly, subclonal and amplification concordance rates for patients in the test before treatment and test after treatment groups are summarized in the table. Moreover, the median of highest VAF% was noted to be 3.1% and 1.1% in test before treatment and test after treatment groups respectively (p value: 0.092).Table:
622P Summary of concordance rates by timing of liquid biopsy test
Test before treatment (N = 27) | Test after treatment (N = 65) | Total (N = 92) | P value | |
---|---|---|---|---|
*Clonal Concordance | 26: 96.3 (81.0, 99.9) | 42: 64.6 (51.8, 76.1) | 68: 73.9 (63.7, 82.5) | 0.001 |
BRAF | 27: 100.0 (87.2, 100.0) | 64: 98.5 (91.7, 100.0) | 91: 98.9 (94.1, 100.0) | 1.000 |
RAS | 26: 96.3 (81.0, 99.9) | 52: 80.0 (68.2, 88.9) | 78: 84.8 (75.8, 91.4) | 0.058 |
Subclonal Concordance | 21: 77.8 (57.7, 91.4) | 44: 67.7 (54.9, 78.8) | 65: 70.7 (60.2, 79.7) | 0.452 |
BRAF | 27: 100.0 (87.2, 100.0) | 65: 100.0 (94.5, 100.0) | 92: 100.0 (96.1, 100.0) | 1.000 |
RAS | 27: 100.0 (87.2, 100.0) | 62: 95.4 (87.1, 99.0) | 89: 96.7 (90.8, 99.3) | 0.553 |
Amplification Concordance | 22: 81.5 (61.9, 93.7) | 41: 63.1 (50.2, 74.7) | 63: 68.5 (58.0, 77.8) | 0.092 |
Highest Variant Allele Frequency (VAF)% | 3.1 (0.0, 84.6) | 1.1 (0.0, 90.1) | 1.5 (0.0, 90.1) | 0.092 |
Concordance rates are summarized by count: percent (95% binomial confidence interval). P values arise from Fisher’s exact tests; *Arbitrarily, 50% of the highest variant allele frequency (VAF)% value in the liquid biopsy results has been used to differentiate clonal from subclonal mutations. Highest VAF% is summarized by median (range). P values arise from Wilcoxon rank sum test
Conclusions
Liquid biopsies show a very high concordance rate in patients with metastatic colorectal cancer. It is important to take the timing of the assay into consideration alongside relevant clonal mutations while assessing the concordance of liquid biopsies, not just for mCRC but for other malignancies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4331 - STING Agonist, ADU-S100, Yields Potent Antitumor Activity and Therapeutically Favorable Immune Profile in an Esophageal Adenocarcinoma Model
Presenter: Ali Zaidi
Session: Poster Display session 2
Resources:
Abstract
1770 - Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract
3755 - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: a GISCAD trial.
Presenter: Roberto Labianca
Session: Poster Display session 2
Resources:
Abstract
2439 - The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry
Presenter: Tae-yong Kim
Session: Poster Display session 2
Resources:
Abstract
2211 - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.
Presenter: Yelena Janjigian
Session: Poster Display session 2
Resources:
Abstract
3046 - Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer (NCT03425058)
Presenter: Tao Fu
Session: Poster Display session 2
Resources:
Abstract
4628 - Gastric cancer screening in BRCA 2 gene mutation carriers: should it be recommended?
Presenter: Inês Oliveira
Session: Poster Display session 2
Resources:
Abstract
2127 - Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Presenter: Yu Sunakawa
Session: Poster Display session 2
Resources:
Abstract
2264 - Prediction of S-1 adjuvant chemotherapy efficacy in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
Presenter: Masanori Terashima
Session: Poster Display session 2
Resources:
Abstract
2444 - Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in Oesophageal adenocarcinoma
Presenter: Emma Ococks
Session: Poster Display session 2
Resources:
Abstract